{"id":13553,"date":"2011-11-15T08:00:46","date_gmt":"2011-11-15T13:00:46","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=13553"},"modified":"2011-11-15T08:19:16","modified_gmt":"2011-11-15T13:19:16","slug":"saturn-regression-trial-gorilla-statin-and-statin-king-battle-to-a-draw","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/11\/15\/saturn-regression-trial-gorilla-statin-and-statin-king-battle-to-a-draw\/","title":{"rendered":"SATURN Regression Trial: Gorilla Statin and Statin King Battle to a Draw"},"content":{"rendered":"<p>An epic battle comparing the two most potent statins &#8212; the reigning king atorvastatin versus &#8220;gorilla statin&#8221; rosuvastatin &#8212; has ended with a quiet draw.\u00a0Results of\u00a0<a href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00620542?term=saturn&amp;rank=3&amp;show_locs=Y#locn\">SATURN<\/a>\u00a0(<strong>S<\/strong>tudy of Coronary <strong>A<\/strong>theroma by In<strong>T<\/strong>ravascular\u00a0<strong>U<\/strong>ltrasound: Effect of\u00a0<strong>R<\/strong>osuvastatin Versus Atorvastati<strong>N<\/strong>) were presented at the AHA on Tuesday and <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1110874\">published simultaneously in the\u00a0<\/a><em><a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1110874\">New England Journal of Medicine<\/a>.<\/em><\/p>\n<p>Stephen Nicholls and colleagues\u00a0randomized 1039 patients with coronary disease to rosuvastatin or atorvastatin for 2 years\u00a0and measured the progression of atherosclerosis using intravascular ultrasound (IVUS).\u00a0As anticipated, after 2 years, lipid parameters were more favorable with rosuvastatin than with atorvastatin:<\/p>\n<ul>\n<li>LDL: 62.6 mg\/dL with rosuvastatin versus 70.2 mg\/dL with atorvastatin (p&lt;0.001)<\/li>\n<li>HDL: 50.4 versus 48.6 mg\/dL (p=0.01)<\/li>\n<\/ul>\n<div>\n<p>However, there was no significant difference in the percent atheroma volume (PAV), the primary efficacy endpoint, which decreased by 0.99% with atorvastatin and 1.22% with rosuvastatin (p=0.17). A secondary endpoint, normalized total atheroma volume (TAV), significantly favored rosuvastatin (-6.39 mm(3) versus -4.42 mm(3), p=0.01). Regression of atherosclerosis, as measured by both PAV and TAV, occurred in a majority of patients in both treatment groups.<\/p>\n<p>Although the trial failed to find a difference between the agents, &#8220;it does show that high-dose, intensive statin therapy can be administered safely and can promote regression of atherosclerotic plaque to a greater extent than has previously been reported,&#8221; the authors conclude.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>An epic battle comparing the two most potent statins &#8212; the reigning king atorvastatin versus &#8220;gorilla statin&#8221; rosuvastatin &#8212; has ended with a quiet draw.\u00a0Results of\u00a0SATURN\u00a0(Study of Coronary Atheroma by InTravascular\u00a0Ultrasound: Effect of\u00a0Rosuvastatin Versus AtorvastatiN) were presented at the AHA on Tuesday and published simultaneously in the\u00a0New England Journal of Medicine. Stephen Nicholls and colleagues\u00a0randomized [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,7],"tags":[585,666,1042,216,584],"class_list":["post-13553","post","type-post","status-publish","format-standard","hentry","category-cardiac-imaging","category-prevention","tag-atorvastatin","tag-ivus","tag-regression","tag-rosuvastatin","tag-statins"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/13553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=13553"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/13553\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=13553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=13553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=13553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}